Print Page      Close Window     

2019 Press Releases

Keyword Search
 
March 6, 2019
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in March
SAN CARLOS, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will participate and present at the following investors conferences in March: Cowen and Company 39th Annual Health Care Conference in Boston, March 11-13, 2019 Location: Boston Marriott Copley Place Date/Time: Wednesday, Ma... More »
February 27, 2019
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
- Patient Enrollment Commenced in the Registrational Cohort 4 in Study of Lifileucel in Advanced Melanoma - - FDA Granted Fast Track Designation for LN-145 for Treatment of Patients with Recurrent, Metastatic or Persistent Cervical Cancer - - Company to Host Conference Call at 4:30 pm EST Today - SAN CARLOS, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymph... More »
February 26, 2019
Iovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical Cancer
SAN CARLOS, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LN-145 for the treatment of patients with recurrent, metastatic or persistent cervical cancer who have progressed while on or after chemotherapy. LN-145 is the Company's adopti... More »
February 22, 2019
Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019
SAN CARLOS, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its fourth quarter and year-end 2018 financial results on Wednesday, February 27, 2019. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EST. To participate... More »
February 1, 2019
Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences
SAN CARLOS, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will participate and present at the following upcoming conferences: 5th Annual Immuno-Oncology 360° conference in New York, February 6-8, 2019 Presenter: Maria Fardis, Ph.D., President and Chief Executive Officer Session: Next Generati... More »